Continuous Elotuzumab, Pomalidomide and Dexamethasone Maintenance Following Second Autologous Transplant for Multiple Myeloma: Results of a Prospective, Phase 2 Multicenter Trial

Upfront autologous hematopoietic cell transplant (AHCT) with melphalan-based conditioning remains a cornerstone of therapy for fit patients with newly diagnosed multiple myeloma, with multiple randomized clinical trials demonstrating a progression-free survival (PFS) benefit associated with upfront versus delayed AHCT in this setting.1 –5 Second (or “salvage”) AHCT (AHCT2) has been widely employed historically, though its use has declined with the emergence of additional agents for advanced disease.

Source: Biology of Blood and Marrow Transplantation - September 21, 2023 Category: Hematology Authors: Michael Slade, Mark A Fiala, Marie Kirchmeyer, Jeff King, Feng Gao, Mark A. Schroeder, A. Keith Stewart, Keith Stockerl-Goldstein, Christine Chen, Ravi Vij Source Type: research